Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy

References

• Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(9–17).
   PubMed Web of Science ®Google Scholar
• Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–882.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Polychronopoulos P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34:368–377.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 2007;13:399–403.
   PubMed Web of Science ®Google Scholar
• Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–1515.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nature Reviews. Neurology. 2010;6:657–666.
   PubMed Web of Science ®Google Scholar
• Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66:1117–1123.
   Google Scholar
• Bennett BK, Park SB, Lin CS, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2012;20:2959–2967.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29:1472–1478.
   PubMed Web of Science ®Google Scholar
• Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118:5171–5178.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Weimer LH, Wang A, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment. 2011;125(767–774).
   Google Scholar
• Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(311–319).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–3977.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2006;24:3113–3120.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–4753.
   PubMed Web of Science ®Google Scholar
• Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. Journal of Palliative Medicine. 2010;13:1389–1391.
   PubMed Web of Science ®Google Scholar
• Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nursing Research. 2007;56:323–331.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2014;22:2261–2269.
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014 Jul 16;3:366. DOI: 10.1186/2193-1801-3-366. eCollection 2014.
   Google Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(2461–2470).
   PubMed Web of Science ®Google Scholar
• Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch. 2013;67:7–9.
   PubMedGoogle Scholar
• Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Research. 2016;5(F1000 Faculty Rev):1466.
   Google Scholar
• Park HJ. Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol. 2014;67:4–7.
   PubMedGoogle Scholar
• Pachman DR, Barton DL, Watson JC, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clinical Pharmacology and Therapeutics. 2011;90:377–387.
   PubMed Web of Science ®Google Scholar
• Muthuraman A, Singh N, Jaggi AS. Protective effect of Acorus calamus L. in rat model of vincristine induced painful neuropathy: an evidence of anti-inflammatory and anti-oxidative activity. Food Chem Toxicol. 2011;49:2557–2563.
   PubMed Web of Science ®Google Scholar
• Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain. 2008;135:262–270.
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007;8:296–306.
   PubMed Web of Science ®Google Scholar
• McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis. 2002;9:220–233.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Fabbrica D, Minoia C, et al. Carboplatin toxic effects on the peripheral nervous system of the rat. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 1998;9:443–447.
   PubMed Web of Science ®Google Scholar
• Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1992;10:795–803.
   PubMed Web of Science ®Google Scholar
• Meijer C, de Vries EG, Marmiroli P, et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology. 1999;20(883–887).
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Tredici G, Marmiroli P, et al. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992;84:364–371.
   PubMed Web of Science ®Google Scholar
• Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007;27:9451–9457.
   PubMed Web of Science ®Google Scholar
• Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. The Journal of Pharmacology and Experimental Therapeutics. 2008;327:300–307.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Jamieson SM, Subramaniam J, et al. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemotherapy and Pharmacology. 2009;64:847–856.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Ceresa C, Nicolini G, et al. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. Anticancer Research. 2014;34:483–486.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011;81:563–568.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem. 2006;13:2901–2907.
   PubMed Web of Science ®Google Scholar
• Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194–206.
   PubMed Web of Science ®Google Scholar
• Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005;41:1460–1466.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Ferrari S, Sorio M, et al. Brentuximab vedotin: axonal microtubule’s Apollyon. Blood Cancer J. 2015;5:e343.
   PubMed Web of Science ®Google Scholar
• Corbin ZA, Nguyen-Lin A, Li S, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis fungoides and sezary syndrome. J Neurooncol. 2017;132:439–446.
   PubMed Web of Science ®Google Scholar
• Bruna J, Udina E, Ale A, et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Experimental Neurology. 2010;223:599–608.
   PubMed Web of Science ®Google Scholar
• Meregalli C, Canta A, Carozzi VA, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain. 2010;14:343–350.
   PubMed Web of Science ®Google Scholar
• Shahshahan MA, Beckley MN, Jazirehi AR. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. American Journal of Cancer Research. 2011;1:913–924.
   PubMed Web of Science ®Google Scholar
• Chiorazzi A, Canta A, Meregalli C, et al. Antibody against tumor necrosis factor-alpha reduces bortezomib-induced allodynia in a rat model. Anticancer Research. 2013;33:5453–5459.
   PubMed Web of Science ®Google Scholar
• Quartu M, Carozzi VA, Dorsey SG, et al. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. BioMed Research International. 2014;180428:2014.
   Google Scholar
• Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Experimental Neurology. 2007;204:317–325.
   PubMed Web of Science ®Google Scholar
• Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park). 2013;27 Suppl 3:4–10.
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Am J Clin Res. 2011;17:2734–2743.
   Google Scholar
• Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–878.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Critical Reviews in Oncology/Hematology. 2008;66:218–228.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593–1599.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2004;15:1439–1442.
   PubMed Web of Science ®Google Scholar
• Lanzani F, Mattavelli L, Frigeni B, et al. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System: JPNS. 2008;13:267–274.
   PubMed Web of Science ®Google Scholar
• Wilkes G. Peripheral neuropathy related to chemotherapy. Seminars in Oncology Nursing. 2007;23:162–173.
   PubMedGoogle Scholar
• Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245–252.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86:23–31.
   PubMed Web of Science ®Google Scholar
• Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116:2322–2331.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Tunoda T, Takiguchi T, et al. Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncology Research. 2012;20:179–185.
   PubMed Web of Science ®Google Scholar
• Kus T, Aktas G, Kalender ME, et al. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2016;24:1175–1179.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32:1941–1967.
   PubMed Web of Science ®Google Scholar
• Schneider B, Li L, Miller K. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(80s. suppl):abstr 1000.
   Google Scholar
• Speck RM, Sammel MD, Farrar JT, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. Journal of Oncology Practice. 2013;9:e234–40.
   PubMedGoogle Scholar
• Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle & Nerve. 2005;31:301–313.
   PubMed Web of Science ®Google Scholar
• Majithia N, Temkin SM, Ruddy KJ, et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2016;24:1439–1447.
   PubMed Web of Science ®Google Scholar
• Beutler A, Kanwar R, Qin R. Sequencing symptom control: results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials. Proc Am Assoc Cancer Res. 2013 abstr LB–196. DOI: 10.1158/1538-7445.AM2013-LB-196.
   Web of Science ®Google Scholar
• Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Am J Clin Res. 2012;18:5099–5109.
   Google Scholar
• Hertz DL, Roy S, Motsinger-Reif AA, et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2013;24:1472–1478.
   PubMed Web of Science ®Google Scholar
• Sucheston LE, Zhao H, Yao S, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Research and Treatment. 2011;130:993–1002.
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. Jama. 2015;313:815–823.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Nair PP. Diagnostic approach to peripheral neuropathy. Ann Indian Acad Neurol. 2008;11:89–97.
   PubMed Web of Science ®Google Scholar
• Shimozuma K, Ohashi Y, Takeuchi A, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2009;17:1483–1491.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:1297–1300.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479–494.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2013;24:454–462.
   PubMed Web of Science ®Google Scholar
• Von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Investigational New Drugs. 2007;25:173–180.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67:2253–2255.
   PubMed Web of Science ®Google Scholar
• Kautio AL, Haanpaa M, Leminen A, et al. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Research. 2009;29:2601–2606.
   PubMed Web of Science ®Google Scholar
• Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2012;23:200–205.
   PubMed Web of Science ®Google Scholar
• Zimmerman C, Atherton PJ, Pachman D, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2016;24:1071–1078.
   PubMed Web of Science ®Google Scholar
• Hilpert F, Stahle A, Tome O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy – a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2005;13:797–805.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Paul J, Soukop M, et al. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemotherapy and Pharmacology. 1998;41:161–166.
   PubMed Web of Science ®Google Scholar
• Davis ID, Kiers L, MacGregor L, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Am J Clin Res. 2005;11:1890–1898.
   Google Scholar
• Gandara DR, Nahhas WA, Adelson MD, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1995;13:490–496.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Jenison EL, Kim K, et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67:172–177.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31:2627–2633.
   PubMed Web of Science ®Google Scholar
• Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12:355.
   PubMed Web of Science ®Google Scholar
• Guo Y, Jones D, Palmer JL, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2014;22:1223–1231.
   PubMed Web of Science ®Google Scholar
• Loven D, Levavi H, Sabach G, et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care (Engl). 2009;18:78–83.
   PubMed Web of Science ®Google Scholar
• Oki E, Emi Y, Kojima H, et al. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. International Journal of Clinical Oncology. 2015;20:767–775.
   PubMed Web of Science ®Google Scholar
• Leal AD, Qin R, Atherton PJ, et al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–1897.
   PubMed Web of Science ®Google Scholar
• Lin PC, Lee MY, Wang WS, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2006;14:484–487.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32:997–1005.
   PubMed Web of Science ®Google Scholar
• Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–766.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Hernandez-Pedro N, Fernandez-Gonzalez-Aragon MC, et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology. 2011;77(987–995).
   Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1996;14:2101–2112.
   PubMed Web of Science ®Google Scholar
• Planting AS, Catimel G, De Mulder PH, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 1999;10:693–700.
   PubMed Web of Science ®Google Scholar
• Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21:1767–1774.
   PubMed Web of Science ®Google Scholar
• Kanat O, Evrensel T, Baran I, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20:237–245.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2003;14:1086–1093.
   PubMed Web of Science ®Google Scholar
• Zhang RX, Lu ZH, Wan DS, et al. Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial. Int J Colorectal Dis. 2012;27:1645–1650.
   PubMed Web of Science ®Google Scholar
• Koeppen S, Verstappen CC, Korte R, et al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma. J Cancer Res Clin Oncol. 2004;130:153–160.
   PubMed Web of Science ®Google Scholar
• Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21:927–931.
   PubMed Web of Science ®Google Scholar
• Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemotherapy and Pharmacology. 2008;61:105–111.
   PubMed Web of Science ®Google Scholar
• Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist. 2007;12:312–319.
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Shaaban SY, Elbarbary NS, et al. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hematol Oncol. 2010;32:594–600.
   PubMed Web of Science ®Google Scholar
• Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med. 1988;84:1016–1022.
   PubMed Web of Science ®Google Scholar
• Shirao K, Matsumura Y, Yamada Y, et al. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol. 2006;36:295–300.
   PubMed Web of Science ®Google Scholar
• Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin the first-line treatment of ± reduced glutathione in advanced ovarian cancer. Int J Gynecol Cancer. 1996;6:415–419.
   Web of Science ®Google Scholar
• Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20:3478–3483.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1995;13:26–32.
   PubMed Web of Science ®Google Scholar
• Milla P, Airoldi M, Weber G, et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs. 2009;20:396–402.
   PubMed Web of Science ®Google Scholar
• Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 1997;8:569–573.
   PubMed Web of Science ®Google Scholar
• Nishioka M, Shimada M, Kurita N, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. International Journal of Clinical Oncology. 2011;16:322–327.
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Am J Clin Res. 2004;10:4055–4061.
   Google Scholar
• Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin administration and time to treatment failure in metastatic colorectal cancer: final results of the phase III CONcePT trial. J Clin Oncol. 2008;26s(abstr 4010). DOI: 10.1200/jco.2008.26.15_suppl.4010.
   Google Scholar
• Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29:421–427.
   PubMed Web of Science ®Google Scholar
• Chay WY, Tan SH, Lo YL, et al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol. 2010;6:270–277.
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Okada N, Miyazaki T, et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. International Journal of Clinical Oncology. 2010;15:82–87.
   PubMed Web of Science ®Google Scholar
• Hochster H, Grothey A, Shpilsky A et al. Effect of intravenous (IV) calcium and magnesium vs placebo on response to FOLFOX + bevacizumab in the CONcePT trial. Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2008).
   Google Scholar
• Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26:1188–1189, author reply 9-90
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005;64:26–31.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage. 2006;32:237–244.
   PubMed Web of Science ®Google Scholar
• Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(1925–1928).
   Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet. Oncol. 2011;12:431–440.
   PubMed Web of Science ®Google Scholar
• Streckmann F, Kneis S, Leifert JA, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2014;25:493–499.
   PubMed Web of Science ®Google Scholar
• Kleckner I, Kamen C, Peppone L. A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients. J Clin Oncol. 2016;34(suppl; abstr 10000). DOI: 10.1200/JCO.2016.34.15_suppl.10000.
   Web of Science ®Google Scholar
• Courneya KS, McKenzie DC, Mackey JR, et al. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy. Br J Cancer. 2014;111:1718–1725.
   PubMed Web of Science ®Google Scholar
• Greenlee H, Hershman DL, Shi Z, et al. Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: the PAthways study. J Clin Oncol. 2016;34(suppl; abstr 10002). DOI: 10.1200/JCO.2016.34.15_suppl.10002.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers AJ, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv. 2015;9:512–522.
   PubMed Web of Science ®Google Scholar
• Stevinson C, Steed H, Faught W, et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer. 2009;19:73–78.
   PubMed Web of Science ®Google Scholar
• Hanai A, Ishiguro H, Sozu T. The effects of frozen gloves and socks on paclitaxel-induced peripheral neuropathy among patients with breast cancer: A self-controlled clinical trial. J Clin Oncol. 2016;34:suppl; abstr 10022.
   Web of Science ®Google Scholar
• Hsu HY, Shieh SJ, Kuan TS, et al. Manual tactile test predicts sensorimotor control capability of hands for patients with peripheral nerve injury. Arch Phys Med Rehabil. 2016;97:983–990.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama. 2013;309:1359–1367.
   PubMed Web of Science ®Google Scholar
• Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98:195–203.
   PubMed Web of Science ®Google Scholar
• Kautio AL, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35:31–39.
   PubMed Web of Science ®Google Scholar
• Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–2118.
   PubMed Web of Science ®Google Scholar
• Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112:2802–2808.
   PubMed Web of Science ®Google Scholar
• Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2011;19:833–841.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118.
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420.
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356.
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Ishitani K, Sato Y, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. International Journal of Clinical Oncology. 2015;20:866–871.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Prevention and treatment of chemotherapy-induced peripheral neuropathy in subjects with advanced colorectal cancer. [ cited 2014 May 02]. http://clinicaltrials.gov/ct2/show/NCT00380874.
   Google Scholar
• Sands S, Ladas EJ, Kelly KM, et al. Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2017;25:701–708.
   PubMed Web of Science ®Google Scholar
• Davies SJ, Harding LM, Baranowski AP. A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain. 2002;18:200–202.
   PubMed Web of Science ®Google Scholar
• Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008;119:2507–2512.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Coyne PJ, Parker GL, et al. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare(R)) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage. 2010;40:883–891.
   PubMed Web of Science ®Google Scholar
• Coyne PJ, Wan W, Dodson P, et al. A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. Journal of Pain & Palliative Care Pharmacotherapy. 2013;27:359–364.
   PubMedGoogle Scholar
• Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol – a TRPM8 agonist. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2015;23:2769–2777.
   PubMed Web of Science ®Google Scholar